Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cefepime hydrochloride
Drug ID BADD_D00387
Description Cefepime is a fourth-generation cephalosporin antibiotic developed in 1994. Cefepime is active against Gram-positive and Gram-negative bacteria, with greater activity against both than third-generation antibiotics. Cefepime is usually reserved to treat severe nosocomial pneumonia, infections caused by multi-resistant microorganisms (e.g. Pseudomonas aeruginosa) and empirical treatment of febrile neutropenia.
Indications and Usage For the treatment of pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae, or Enterobacter species. Also for empiric treatment of febrile neutropenic patients and uncomplicated and complicated urinary tract infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Also for the treatment of uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible strains only) or Streptococcus pyogenes and complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterobacter species, or Bacteroides fragilis.
Marketing Status approved; investigational
ATC Code J01DE01
DrugBank ID DB01413
KEGG ID D01157
MeSH ID D000077723
PubChem ID 9571075
TTD Drug ID D0A1CB
NDC Product Code 70594-090; 71288-009; 71288-008; 67184-1003; 67184-1004; 63785-113; 25021-121; 0264-3195; 25021-122; 70594-089; 0264-3193; 67184-1002
UNII I8X1O0607P
Synonyms Cefepime | Cefepim | Cefepime Hydrochloride | Maxipime | Axépim | Quadrocef | BMY 28142 | BMY-28142 | BMY28142
Chemical Information
Molecular Formula C19H28Cl2N6O6S2
CAS Registry Number 123171-59-5
SMILES C[N+]1(CCCC1)CC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)O.O.Cl.[Cl-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Activated partial thromboplastin time prolonged13.01.02.001--
Agranulocytosis01.02.03.001---
Alanine aminotransferase increased13.03.04.005--
Anaemia01.03.02.001--
Anaphylactic shock10.01.07.002; 24.06.02.004---
Aphasia17.02.03.001; 19.21.01.001--
Aplastic anaemia01.03.03.002---
Aspartate aminotransferase13.03.04.008---
Colitis07.08.01.001--
Coma17.02.09.001---
Confusional state17.02.03.005; 19.13.01.001--
Diarrhoea07.02.01.001--
Eosinophil count13.01.06.021---
Erythema23.03.06.001---
Erythema multiforme10.01.03.015; 23.03.01.003--
Haemolytic anaemia01.06.03.002---
Hallucination19.10.04.003--
Headache17.14.01.001--
Hepatic function abnormal09.01.02.001---
Leukopenia01.02.02.001---
Myoclonus17.02.05.008---
Nausea07.01.07.001--
Nephropathy toxic12.03.01.010; 20.05.03.002---
Neutropenia01.02.03.004---
Oral candidiasis07.05.07.001; 11.03.03.004---
Pain08.01.08.004--
Phlebitis12.02.01.002; 24.12.03.004--
Prothrombin time13.01.02.038---
Pruritus23.03.12.001--
Pseudomembranous colitis07.19.01.003; 11.02.02.002---
The 1th Page    1 2    Next   Last    Total 2 Pages